BrightGene plans H-share listing, proposes buyback and board expansion

BrightGene Bio-Medical Technology is planning to issue H-shares and list them on the Main Board of The Stock Exchange of Hong Kong Limited. This move aims to accelerate its international strategy, enhance financing capabilities, and strengthen overall competitiveness. The company will revise its Articles of Association and other internal governance documents to comply with relevant Hong Kong and mainland regulations. Shareholders will vote on these proposals at the First Extraordinary General Meeting of 2025 on October 17, 2025.

In preparation for the H-share listing, BrightGene will increase its board of directors from nine to eleven members, adding one new independent non-executive director and one employee representative director. PricewaterhouseCoopers has been appointed as the auditor for the H-share listing. Additionally, BrightGene plans to provide financial assistance of up to CNY 20,000 million to its controlled subsidiary, Atterx (Suzhou) Pharmaceutical Technology Co., Ltd. through a loan, to support its operational expansion. This loan will be subject to an interest rate benchmarked to the national interbank lending rate.

The company also announced a share buyback program of CNY 1,000 million to CNY 2,000 million, to be used for equity incentive or employee stock ownership plans. The buyback price will not exceed CNY 139.77 per share. These initiatives are part of BrightGene's strategy to enhance corporate governance, optimize capital structure, and expand its global footprint.